DrugPatentWatch Database Preview
Patent: 8,883,156
Summary for Patent: 8,883,156
| Title: | Purified antibody composition |
| Abstract: | The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained. |
| Inventor(s): | Wan; Min M. (Worcester, MA), Avgerinos; George (Sudbury, MA), Zarbis-Papastoitsis; Gregory (Watertown, MA) |
| Assignee: | AbbVie Biotechnology Ltd. (Hamilton, BM) |
| Application Number: | 13/927,576 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,883,156 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,883,156
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | HUMIRA | adalimumab | SYRINGE | 125057 | 001 | 2002-12-31 | Start Trial | AbbVie Biotechnology Ltd. (Hamilton, BM) | 2026-04-05 | RX | search | |
| Abbvie Inc | HUMIRA | adalimumab | VIAL | 125057 | 002 | 2002-12-31 | Start Trial | AbbVie Biotechnology Ltd. (Hamilton, BM) | 2026-04-05 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
